Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa

Journal of Medicinal Chemistry

Volumn 47, Issue 16, 2004, Pages 4089-4099

  Willardsen, J Adam ^a,b   Dudley, Danette A ^a   Cody, Wayne L ^a   Chi, Liguo ^a   McClanahan, Thomas B ^a   Mertz, Thomas E ^a   Potoczak, Ronald E ^a   Narasimhan, Lakshmi S ^a   Holland, Debra R ^a   Rapundalo, Stephen T ^a   Edmunds, Jeremy J ^a  

^a PFIZER INC   (United States)

^b Myriad Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 [5 (2,6 DIMETHYLPIPERIDIN 1 YL)PENTYL] 3 OXO 3,4 DIHYDROQUINOXOLIN 2 YL]BENZAMIDINE; ANTICOAGULANT AGENT; BENZAMIDINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A ANTAGONIST; QUINOXALINE DERIVATIVE; THROMBIN; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY INJURY; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ELECTRIC INJURY; ENZYME INHIBITION; IC 50; NONHUMAN; RABBIT; STRUCTURE ACTIVITY RELATION; VEIN INJURY; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BENZAMIDINES; CRYSTALLOGRAPHY, X-RAY; DOGS; DRUG DESIGN; FACTOR XA; HUMANS; MOLECULAR STRUCTURE; PROTEIN BINDING; QUINOXALINES; RABBITS; SERINE PROTEINASE INHIBITORS; SPECIES SPECIFICITY; THROMBOSIS;

EID: 3242776164     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0497491     Document Type: Article

References (33)

1. Anonymous. From the Centers for Disease Control and Prevention. Decline in deaths from heart disease and stroke United States, 1900-1999. JAMA, J. Am. Med. Assoc. 1999, 282, 724-726.
2. Bick, R. L.; Kaplan, H. Syndromes of thrombosis and hypercoagulability. Congenital and acquired causes of thrombosis. Med. Clin. North Am. 1998, 82, 409-458.
3. Mousa, S. A. Highlights of latest advances in antithrombotics. Methods Mol. Med. 2004, 93, 1-7. Turpie, A. G. G. Antithrombotics and anticoagulants in coronary syndromes and stroke. Semin. Thrombosis Hemostasis 2000, 26 (Suppl. 1), 79-83. Agnelli, G.; Sonaglia, F. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. Haematologica 2002, 87, 757-770.
4. Mousa, S. A. Highlights of latest advances in antithrombotics. Methods Mol. Med. 2004, 93, 1-7. Turpie, A. G. G. Antithrombotics and anticoagulants in coronary syndromes and stroke. Semin. Thrombosis Hemostasis 2000, 26 (Suppl. 1), 79-83. Agnelli, G.; Sonaglia, F. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. Haematologica 2002, 87, 757-770.
5. Mousa, S. A. Highlights of latest advances in antithrombotics. Methods Mol. Med. 2004, 93, 1-7. Turpie, A. G. G. Antithrombotics and anticoagulants in coronary syndromes and stroke. Semin. Thrombosis Hemostasis 2000, 26 (Suppl. 1), 79-83. Agnelli, G.; Sonaglia, F. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. Haematologica 2002, 87, 757-770.
6. Kimball, D. Thrombin active site inhibitors. Curr. Pharm. Des. 1995, 1, 441-468. Steinmetzer, T., Hauptmann, J.; Sturzebecher, J. Expert Opin. Invest. Drugs 2001, 10, 845-864.
7. Kimball, D. Thrombin active site inhibitors. Curr. Pharm. Des. 1995, 1, 441-468. Steinmetzer, T., Hauptmann, J.; Sturzebecher, J. Expert Opin. Invest. Drugs 2001, 10, 845-864.
8. Ewing, W. R.; Pauls, H. W.; Spada, A. P. Progress in the design of inhibitors of coagulation factor Xa. Drugs Future 1999, 24, 771-787. Sinha, J. Synthetic inhibitors of coagulation factor Xa. Expert Opin. Invest. Drugs 1999, 8, 567-573.
9. Ewing, W. R.; Pauls, H. W.; Spada, A. P. Progress in the design of inhibitors of coagulation factor Xa. Drugs Future 1999, 24, 771-787. Sinha, J. Synthetic inhibitors of coagulation factor Xa. Expert Opin. Invest. Drugs 1999, 8, 567-573.
10. Rapaport, S. I.; Rao, L. V. M. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler. Thromb. 1992, 12, 1111-1121.
11. Harker, L. A.; Maraganore, J. M.; Hirsh, J. Novel antithrombotic agents. In Hemostasis and Thrombosis: Basic Priniciples and Clinical Practice, 3rd ed.; Colman, R. W.; Hirsh, J.; Marder, V. J.; Eds.; Lippincott Company: Philadelphia, PA, 1994; pp 1638-1660.
12. Dudley, D. A.; Bunker, A. M.; Chi, L.; Cody, W. L.; Holland, D. R. et al. Rational Design, synthesis, and biological activity of benzoxazinones as novel Factor Xa inhibitors. J. Med. Chem. 2000, 43, 4063-4070.
13. Walsmann, P. Inhibition of serine proteinases by benzamidine derivatives. Acta Biol. Med. Ger. 1977, 36, 1931-1937. Phillips, G. B., Buckman, B. O., Davey, D. D. Eagen, K. A., Guilford, W. J. et al. Discovery of N-[2-[5-amino(imino)methyl]-2-hydro-1-methyl-(1H-imidazol-2-yl)) phenoxylpyridin-4-yl]-N-methylglycine (ZK-807834): A potent and orally active inhibitor of the blood coagulation enzyme factor Xa. J. Med. Chem. 1998, 41, 3557-3562.
14. Walsmann, P. Inhibition of serine proteinases by benzamidine derivatives. Acta Biol. Med. Ger. 1977, 36, 1931-1937. Phillips, G. B., Buckman, B. O., Davey, D. D. Eagen, K. A., Guilford, W. J. et al. Discovery of N-[2-[5-amino(imino)methyl]-2-hydro-1-methyl-(1H-imidazol-2-yl)) phenoxylpyridin-4-yl]-N-methylglycine (ZK-807834): A potent and orally active inhibitor of the blood coagulation enzyme factor Xa. J. Med. Chem. 1998, 41, 3557-3562.
15. Berryman, K. A.; Downing, D. M.; Dudley, D. A.; Edmunds, J. J.; Narasimhan, L. S. et al. Preparation of benzoxazinones and -thiazinones as serine protease inhibitors. PCT Int. Appl.; (Warner-Lambert Company, USA).: WO 9250257, 1999; Downing, D. M., Berryman, K. A., Dudley, D. A., Zhu, Z., Pamment, M. et al. Chiral benzoxazinones as potent and selective FXa inhibitors. J. Org. Chem. 2004, submitted.
16. Berryman, K. A.; Downing, D. M.; Dudley, D. A.; Edmunds, J. J.; Narasimhan, L. S. et al. Preparation of benzoxazinones and -thiazinones as serine protease inhibitors. PCT Int. Appl.; (Warner-Lambert Company, USA).: WO 9250257, 1999; Downing, D. M., Berryman, K. A., Dudley, D. A., Zhu, Z., Pamment, M. et al. Chiral benzoxazinones as potent and selective FXa inhibitors. J. Org. Chem. 2004, submitted.
17. Tanaka, H.; Yamashita, S.; Yamanoue, M.; Torii, S. Reductive addition of polyhalomethanes and their related compounds to aldehydes and 1,2-elimination of the coupling products in a palladium/aluminum bimetal redox system. J. Org. Chem. 1989, 54, 444-450.
18. Gukasyan, A. K.; Galstyan, L. K.; Avetisyan, A. A. Investigations in the field of (trihalomethyl) carbinols. IV. Block-addition reaction of aromatic 1,4-dinucleophiles to gem-dichloro epoxides generated from aryl(trichloromethyl) carbinols. Arm. Khim. Zh. 1988, 41, 572-575.
19. Granik, V. G. Advances in chemistry of amidines. Usp. Khim. 1983 52, 669-703.
20. Dunn, P. J. Amidines and N-substituted amidines. Compr. Org. Funct. Group Transform. 1995, 5, 741-782, 1161-1308.
21. Judkins, B. D.; Allen, D. G.; Cook, T. A.; Evans, B.; Sardharwala, T. E. A versatile synthesis of amidines from nitriles via amidoximes. Synth. Commun. 1996, 26, 4351-4367.
22. Duclos, R. I., Jr.; Tung, J. S.; Rapoport, H. A high-yield modification of the Pschorr phenanthrene synthesis. J. Org. Chem. 1984, 49, 5243-5246.
23. Selnick, H. G.; Smith, G. R.; Tebben, A. J. An improved procedure for the cyanation of aryl trifiates: a convenient synthesis of 6-cyano-1,2,3,4- tetrahydroisoquinoline. Synth. Commun. 1995, 25, 3255-3261.
24. Timari, G.; Soos, T.; Hajos, G. A convenient synthesis of two new indoloquinoline alkaloids. Synlett 1997, 1067-1068.
25. Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. (Washington, D. C.) 1995, 95, 2457-2483.
26. Nitta, I.; Fujimori, S.; Ueno, H. The syntheses of the corticoid side chain. I. An improved method for the preparation of 17.alpha.- hydroxyprogesterone from androst-4-ene-3, 17-dione. Bull. Chem. Soc. Jpn. 1985, 58, 978-980.
27. Chi, L.; Saganek, L.; Rogers, K.; Mertz, T.; Metz, A.; et al. A novel model of venous thrombosis in the vena cava of rabbits. J. Pharmacol. Toxicol. Methods 1988, 39, 193-202.
28. McClanahan, T. B.; Ignasiak, D. P.; Juneau, P.; Finkle, C.; Winocour, P. D. et al. Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis. J. Thromb. Thrombolysis 1999, 7, 301-306; Ignasiak, D. P.; McClanahan, T. B.; Bousley, R. E.; Juneau, P. L.; Gallagher, K. P. Effects of intravenous enoxaparin and intravenous inogatran in an electrolytic injury model of venous thrombosis in the dog. J. Thromb. Thrombolysis 1998, 6, 199-206.
29. McClanahan, T. B.; Ignasiak, D. P.; Juneau, P.; Finkle, C.; Winocour, P. D. et al. Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis. J. Thromb. Thrombolysis 1999, 7, 301-306; Ignasiak, D. P.; McClanahan, T. B.; Bousley, R. E.; Juneau, P. L.; Gallagher, K. P. Effects of intravenous enoxaparin and intravenous inogatran in an electrolytic injury model of venous thrombosis in the dog. J. Thromb. Thrombolysis 1998, 6, 199-206.
30. Topliss, J. G. A manual method for applying the hansch approach to drug design. Med. Chem. Proc. Int. Symp. 5th 1977, 421-426. Topliss, J. G. Utilization of operational schemes for analogue synthesis in drug design. J. Med. Chem. 1972, 15, 1006-1011.
31. Topliss, J. G. A manual method for applying the hansch approach to drug design. Med. Chem. Proc. Int. Symp. 5th 1977, 421-426. Topliss, J. G. Utilization of operational schemes for analogue synthesis in drug design. J. Med. Chem. 1972, 15, 1006-1011.
32. Bode, W.; Schwager, P. The refined crystal structure of bovine beta-trypsin at 1.8 A resolution. II. Crystallographic refinement, calcium binding site, benzamidine binding site and active site at pH 7.0. J. Mol. Biol. 1975, 98, 693-717.
33. Brunger, A. T. Xplor A system for X-ray crystallography and NMR; Yale University Press: New Haven, CT, 1992.